New and future therapies for lupus nephritis.
Cleve Clin J Med. 2012 Feb;79(2):134-40
Authors: Appel GB
Based on data from randomized controlled trials over the past decade, oral mycophenolate (CellCept) now rivals intravenous cyclophosphamide (Cytoxan) as a first-line therapy for lupus nephritis, offering similar efficacy but less toxicity. The roles of rituximab (Rituxan) and new immunomodulatory agents are being explored. Creativity in treating lupus nephritis is needed; one regimen does not fit all.
PMID: 22301564 [PubMed - in process]